Plus, news about Boston Oncology, Garda and Assertio, an Everest deal and Forte’s raise:
🟢 FDA ends partial hold on MacroGenics cancer drug: In February, the agency stopped a Phase 2 trial of lorigerlimab after …
Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.
Boehringer has altered the terms of its digital therapeutic alliance with Click on schizophrenia app CT-155, taking a more strategic investor role.
Novartis is launching a three-front push to close healthcare gaps in heart disease and cancer, expanding initiatives with the goal of roughly tripling their footprint
The FDA is again looking into the safety of the abortion drug mifepristone following a Louisiana court order and calls from Republican lawmakers to investigate
AbbVie filed suit against the federal government on Wednesday over its interpretation of the word “patient” under the 340B federal drug discount program. The lawsuit
Plus, news about Boston Oncology, Garda and Assertio, an Everest deal and Forte’s raise:
🟢 FDA ends partial hold on MacroGenics cancer drug: In February, the agency stopped a Phase 2 trial of lorigerlimab after …